Listener effort quantifies clinically meaningful progression of dysarthria in people living with amyotrophic lateral sclerosis

Competing Interest Statement

INB is the founder of Everything ALS. RN is an employee of IBM Research. EGR is a paid consultant to Everything ALS. JP is a paid consultant to Everything ALS. MAT is a paid consultant to Everything ALS. CA is an employee of IBM Research. DES is a paid consultant to Everything ALS. FA is a paid consultant to Everything ALS. IE is a paid consultant to Everything ALS. AT was a paid consultant to Everything ALS. Work was done while working at EverythingALS. Currently he is an employee of SRI International. DH is a paid consultant to Everything ALS. AW is an employee of Atrium Health (part of Advocate Health) and a paid consultant to Everything ALS. KS is a paid consultant to Everything ALS. SS is a paid consultant to Everything ALS. JG reports research grants from the National Institutes of Health, MT Pharma of America, and Modality AI. He has also served as a paid consultant for Google, Biogen, and Takeda; and an unpaid consultant for Everything ALS. LWO reports current research support from NINDS and the CDC National ALS Biorepository, and unpaid advisory board membership for Everything ALS and the ALS Hope Foundation.Ernest Fraenkel is an unpaid advisor to Everything ALS. JDB reports research grants from Biogen, MT Pharma of America, Alexion, Rapa Therapeutics, the ALS Association, the Muscular Dystrophy Association, ALS One, Tambourine, ALS Finding a Cure, NINDS, personal consulting fees from Biogen, MT Pharma of America, Regeneron, Roon, and Sanofi, and unpaid advisory board membership for ALS One and Everything ALS.

Funding Statement

This study was funded by Everything ALS.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All aspects of the design and conduct of the Everything ALS Speech Study are done under the approval of the Western IRB.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes